This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
UTHR Tops Q4 Earnings Estimates, Shares Surge 13% on Strong Guidance
by Zacks Equity Research
United Therapeutics Q4 earnings beat estimates, Tyvaso DPI sales jump 24% despite revenue miss.
UTHRPositive Net Change ANIPNegative Net Change ASRTNegative Net Change CSTLNegative Net Change
biotechs
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
by Zacks Equity Research
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
SNYPositive Net Change BMYPositive Net Change BAYRYNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
BEAMNegative Net Change ASRTNegative Net Change CSTLNegative Net Change HRMYNegative Net Change
biotechs
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
by Zacks Equity Research
Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.
IOVAPositive Net Change ASRTNegative Net Change CSTLNegative Net Change HRMYNegative Net Change
biotechs
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
by Zacks Equity Research
Jazz Pharmaceuticals beats Q4 earnings and revenue estimates as neuroscience and oncology sales climb, sending shares up 5% in after hours.
JAZZPositive Net Change CSTLNegative Net Change IMCRPositive Net Change
biotechs cannabis earnings medical
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
by Zacks Equity Research
Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.
CSTLNegative Net Change HRMYNegative Net Change IMCRPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
RGEN tops Q4 EPS estimates as revenues jump 18% Y/Y, with solid organic growth and stronger margins heading into 2026.
RGENNegative Net Change CSTLNegative Net Change HRMYNegative Net Change IMCRPositive Net Change
biotechs earnings
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
by Zacks Equity Research
APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
APLSNegative Net Change CSTLNegative Net Change HRMYNegative Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel
by Zacks Equity Research
Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.
BMYPositive Net Change GILDPositive Net Change ACLXNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
by Zacks Equity Research
Axsome misses Q4 estimates for earnings. Revenues jump 65% on strong Auvelity sales as well as other product sales and top estimates.
JAZZPositive Net Change AXSMPositive Net Change CSTLNegative Net Change HRMYNegative Net Change
biotechs earnings